

# Susan Lee Welkos

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5867199/publications.pdf>

Version: 2024-02-01

54  
papers

2,704  
citations

201674

27  
h-index

206112

48  
g-index

60  
all docs

60  
docs citations

60  
times ranked

1626  
citing authors

#	ARTICLE	IF	CITATIONS
1	Protection Elicited by Attenuated Live <i>Yersinia pestis</i> Vaccine Strains against Lethal Infection with Virulent <i>Y. pestis</i> . <i>Vaccines</i> , 2021, 9, 161.	4.4	12
2	Comparison of three non-human primate aerosol models for glanders, caused by <i>Burkholderia mallei</i> . <i>Microbial Pathogenesis</i> , 2021, 155, 104919.	2.9	4
3	A DUF4148 family protein produced inside RAW264.7 cells is a critical <i>Burkholderia pseudomallei</i> virulence factor. <i>Virulence</i> , 2020, 11, 1041-1058.	4.4	4
4	Laser Scanning Confocal Microscopy Was Used to Validate the Presence of <i>Burkholderia pseudomallei</i> or <i>B. mallei</i> in Formalin-Fixed Paraffin Embedded Tissues. <i>Tropical Medicine and Infectious Disease</i> , 2020, 5, 65.	2.3	0
5	Combinations of early generation antibiotics and antimicrobial peptides are effective against a broad spectrum of bacterial biothreat agents. <i>Microbial Pathogenesis</i> , 2020, 142, 104050.	2.9	20
6	Dysregulation of TNF- $\alpha$ and IFN- $\gamma$ expression is a common host immune response in a chronically infected mouse model of melioidosis when comparing multiple human strains of <i>Burkholderia pseudomallei</i> . <i>BMC Immunology</i> , 2020, 21, 5.	2.2	9
7	The Use of Analgesics during Vaccination with a Live Attenuated <i>Yersinia pestis</i> Vaccine Alters the Resulting Immune Response in Mice. <i>Vaccines</i> , 2019, 7, 205.	4.4	5
8	Characterization of pathogenesis of and immune response to <i>Burkholderia pseudomallei</i> K96243 using both inhalational and intraperitoneal infection models in BALB/c and C57BL/6 mice. <i>PLoS ONE</i> , 2017, 12, e0172627.	2.5	30
9	Animal Models for the Pathogenesis, Treatment, and Prevention of Infection by <i>Bacillus anthracis</i> . , 2016, , 269-311.		0
10	The <i>Bacillus anthracis</i> Exosporium: What's the Big "Hairy" Deal?. <i>Microbiology Spectrum</i> , 2015, 3, .	3.0	25
11	Animal Models for the Pathogenesis, Treatment, and Prevention of Infection by <i>Bacillus anthracis</i> . <i>Microbiology Spectrum</i> , 2015, 3, TBS-0001-2012.	3.0	24
12	Anthrax Toxins in Context of <i>Bacillus anthracis</i> Spores and Spore Germination. <i>Toxins</i> , 2015, 7, 3167-3178.	3.4	18
13	Characterization of <i>Burkholderia pseudomallei</i> Strains Using a Murine Intraperitoneal Infection Model and In Vitro Macrophage Assays. <i>PLoS ONE</i> , 2015, 10, e0124667.	2.5	49
14	A Unique Set of the <i>Burkholderia</i> Collagen-Like Proteins Provides Insight into Pathogenesis, Genome Evolution and Niche Adaptation, and Infection Detection. <i>PLoS ONE</i> , 2015, 10, e0137578.	2.5	27
15	<i>Bacillus anthracis</i> and Other <i>Bacillus</i> Species. , 2015, , 1789-1844.		9
16	Interrogation of the <i>Burkholderia pseudomallei</i> Genome to Address Differential Virulence among Isolates. <i>PLoS ONE</i> , 2014, 9, e115951.	2.5	29
17	Phenotypic changes in spores and vegetative cells of <i>Bacillus anthracis</i> associated with BenK. <i>Microbial Pathogenesis</i> , 2013, 57, 41-51.	2.9	0
18	Immunization of Mice with Formalin-Inactivated Spores from Avirulent <i>Bacillus cereus</i> Strains Provides Significant Protection from Challenge with <i>Bacillus anthracis</i> Ames. <i>Vaccine Journal</i> , 2013, 20, 56-65.	3.1	18

#	ARTICLE	IF	CITATIONS
19	Advanced Development of the rF1V and rBV A/B Vaccines: Progress and Challenges. <i>Advances in Preventive Medicine</i> , 2012, 2012, 1-14.	2.7	30
20	Delayed Toxicity Associated with Soluble Anthrax Toxin Receptor Decoy-Ig Fusion Protein Treatment. <i>PLoS ONE</i> , 2012, 7, e34611.	2.5	13
21	Role of Purine Biosynthesis in <i>Bacillus anthracis</i> Pathogenesis and Virulence. <i>Infection and Immunity</i> , 2011, 79, 153-166.	2.2	49
22	Key aspects of the molecular and cellular basis of inhalational anthrax. <i>Microbes and Infection</i> , 2011, 13, 1146-1155.	1.9	36
23	Allelic Variation on Murine Chromosome 11 Modifies Host Inflammatory Responses and Resistance to <i>Bacillus anthracis</i> . <i>PLoS Pathogens</i> , 2011, 7, e1002469.	4.7	15
24	Cutting Edge: Resistance to <i>Bacillus anthracis</i> Infection Mediated by a Lethal Toxin Sensitive Allele of <i>Nalp1b/Nlrp1b</i> . <i>Journal of Immunology</i> , 2010, 184, 17-20.	0.8	133
25	In Vitro Intracellular Trafficking of Virulence Antigen during Infection by <i>Yersinia pestis</i> . <i>PLoS ONE</i> , 2009, 4, e6281.	2.5	8
26	Roles of the <i>Bacillus anthracis</i> Spore Protein ExsK in Exosporium Maturation and Germination. <i>Journal of Bacteriology</i> , 2009, 191, 7587-7596.	2.2	40
27	Localization and assembly of proteins comprising the outer structures of the <i>Bacillus anthracis</i> spore. <i>Microbiology (United Kingdom)</i> , 2009, 155, 1133-1145.	1.8	46
28	A strategy to verify the absence of the <i>pgm</i> locus in <i>Yersinia pestis</i> strain candidates for select agent exemption. <i>Journal of Microbiological Methods</i> , 2009, 77, 316-319.	1.6	8
29	Early interactions between fully virulent <i>Bacillus anthracis</i> and macrophages that influence the balance between spore clearance and development of a lethal infection. <i>Microbes and Infection</i> , 2008, 10, 613-619.	1.9	37
30	Characterization of a <i>Bacillus anthracis</i> spore coat-surface protein that influences coat-surface morphology. <i>FEMS Microbiology Letters</i> , 2008, 289, 110-117.	1.8	18
31	Modified Caspase-3 Assay Indicates Correlation of Caspase-3 Activity with Immunity of Nonhuman Primates to <i>Yersinia pestis</i> Infection. <i>Vaccine Journal</i> , 2008, 15, 1134-1137.	3.1	20
32	Morphogenesis of the <i>Bacillus anthracis</i> Spore. <i>Journal of Bacteriology</i> , 2007, 189, 691-705.	2.2	125
33	<i>Bacillus anthracis</i> Spores of the <i>bclA</i> Mutant Exhibit Increased Adherence to Epithelial Cells, Fibroblasts, and Endothelial Cells but Not to Macrophages. <i>Infection and Immunity</i> , 2007, 75, 4498-4505.	2.2	78
34	Multivalent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. <i>Vaccine</i> , 2006, 24, 6886-6892.	3.8	37
35	Roles of Macrophages and Neutrophils in the Early Host Response to <i>Bacillus anthracis</i> Spores in a Mouse Model of Infection. <i>Infection and Immunity</i> , 2006, 74, 469-480.	2.2	135
36	The use of a model of in vivo macrophage depletion to study the role of macrophages during infection with <i>Bacillus anthracis</i> spores. <i>Microbial Pathogenesis</i> , 2004, 37, 169-175.	2.9	75

#	ARTICLE	IF	CITATIONS
37	A microtiter fluorometric assay to detect the germination of Bacillus anthracis spores and the germination inhibitory effects of antibodies. Journal of Microbiological Methods, 2004, 56, 253-265.	1.6	49
38	Venezuelan Equine Encephalitis Virus-Vectored Vaccines Protect Mice against Anthrax Spore Challenge. Infection and Immunity, 2003, 71, 1491-1496.	2.2	60
39	The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology (United Kingdom), 2001, 147, 1677-1685.	1.8	201
40	Protection against experimental bubonic and pneumonic plague by a recombinant capsular F1-V antigen fusion protein vaccine. Vaccine, 1998, 16, 1131-1137.	3.8	249
41	Antibiotic Treatment of Experimental Pneumonic Plague in Mice. Antimicrobial Agents and Chemotherapy, 1998, 42, 675-681.	3.2	96
42	Protection of Mice from Fatal Bubonic and Pneumonic Plague by Passive Immunization with Monoclonal Antibodies against the F1 Protein of Yersinia pestis. American Journal of Tropical Medicine and Hygiene, 1997, 56, 471-473.	1.4	92
43	Relationship Between Virulence and Immunity as Revealed in Recent Studies of the F1 Capsule of Yersinia pestis. Clinical Infectious Diseases, 1995, 21, S178-S181.	5.8	139
44	The transformation frequency of plasmids into Bacillus anthracis is affected by adenine methylation. Gene, 1995, 152, 75-78.	2.2	45
45	[2] Determination of median lethal and infectious doses in animal model systems. Methods in Enzymology, 1994, 235, 29-39.	1.0	67
46	Recent advances in the development of an improved, human anthrax vaccine. European Journal of Epidemiology, 1988, 4, 12-19.	5.7	126
47	Comparative safety and efficacy against Bacillus anthracis of protective antigen and live vaccines in mice. Microbial Pathogenesis, 1988, 5, 127-139.	2.9	124
48	Comparison of the one-gramd-[14C]xylose breath test to the [14C]bile acid breath test in patients with small-intestine bacterial overgrowth. Digestive Diseases and Sciences, 1980, 25, 53-58.	2.3	64
49	Detection of Small Intestine Bacterial Overgrowth by Means of a 14C-D-Xylose Breath Test. Gastroenterology, 1979, 77, 75-82.	1.3	96
50	Clinical response of patients with gonococcal endocervicitis and endometritis-salpingitis-peritonitis to doxycycline. American Journal of Obstetrics and Gynecology, 1977, 129, 614-622.	1.3	22
51	CUL-DE-SAC ISOLATES FROM PATIENTS WITH ENDOMETRITIS-SALPINGITIS-PERITONITIS AND GONOCOCCAL ENDOCERVICITIS. Obstetrical and Gynecological Survey, 1977, 32, 113-114.	0.4	0
52	INFECTIOUS MORBIDITY DUE TO BACTEROIDES FRAGILIS IN OBSTETRIC PATIENTS. Clinical Obstetrics and Gynecology, 1976, 19, 131-145.	1.1	2
53	Cul-de-sac isolates from patients with endometritis-salpingitis-peritonitis and gonococcal endocervicitis. American Journal of Obstetrics and Gynecology, 1976, 126, 158-161.	1.3	82
54	The Bacillus anthracis Exosporium: What's the Big "Hairy" Deal?. , 0, , 253-268.		3